Cargando…
Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents
Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522278/ https://www.ncbi.nlm.nih.gov/pubmed/28489578 http://dx.doi.org/10.18632/oncotarget.17254 |
_version_ | 1783252139286462464 |
---|---|
author | Choi, Jung-Suk Kim, Seol Motea, Edward Berdis, Anthony |
author_facet | Choi, Jung-Suk Kim, Seol Motea, Edward Berdis, Anthony |
author_sort | Choi, Jung-Suk |
collection | PubMed |
description | Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visualizes the replication of damaged DNA to identify cells that acquire drug resistance through this mechanism. Visualization is achieved using "click" chemistry to covalently attach azide-containing fluorophores to the ethynyl group present on the nucleoside analog after its incorporation opposite damaged DNA. Flow cytometry and microscopy techniques demonstrate that the extent of nucleotide incorporation into genomic DNA is enhanced by treatment with DNA damaging agents. In addition, this nucleoside analog inhibits translesion DNA synthesis and synergizes the therapeutic activity of certain anti-cancer agents such as temozolomide. The combined diagnostic and therapeutic activities of this synthetic nucleoside analog represent a new paradigm in personalized medicine. |
format | Online Article Text |
id | pubmed-5522278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55222782017-08-21 Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents Choi, Jung-Suk Kim, Seol Motea, Edward Berdis, Anthony Oncotarget Research Paper Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, DNA polymerases can effectively replicate the formed DNA lesions to cause drug resistance and create more aggressive cancers. To understand this process at the cellular level, we developed an artificial nucleoside that visualizes the replication of damaged DNA to identify cells that acquire drug resistance through this mechanism. Visualization is achieved using "click" chemistry to covalently attach azide-containing fluorophores to the ethynyl group present on the nucleoside analog after its incorporation opposite damaged DNA. Flow cytometry and microscopy techniques demonstrate that the extent of nucleotide incorporation into genomic DNA is enhanced by treatment with DNA damaging agents. In addition, this nucleoside analog inhibits translesion DNA synthesis and synergizes the therapeutic activity of certain anti-cancer agents such as temozolomide. The combined diagnostic and therapeutic activities of this synthetic nucleoside analog represent a new paradigm in personalized medicine. Impact Journals LLC 2017-04-19 /pmc/articles/PMC5522278/ /pubmed/28489578 http://dx.doi.org/10.18632/oncotarget.17254 Text en Copyright: © 2017 Choi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Choi, Jung-Suk Kim, Seol Motea, Edward Berdis, Anthony Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title | Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title_full | Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title_fullStr | Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title_full_unstemmed | Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title_short | Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents |
title_sort | inhibiting translesion dna synthesis as an approach to combat drug resistance to dna damaging agents |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522278/ https://www.ncbi.nlm.nih.gov/pubmed/28489578 http://dx.doi.org/10.18632/oncotarget.17254 |
work_keys_str_mv | AT choijungsuk inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents AT kimseol inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents AT moteaedward inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents AT berdisanthony inhibitingtranslesiondnasynthesisasanapproachtocombatdrugresistancetodnadamagingagents |